06/12/2018 15:15:00

Efftec International Inc. Announces Acquisition of Teligent Care, Inc.

Nev., Dec. 06, 2018 (GLOBE NEWSWIRE) -- -Efftec International, Inc. (OTC Pink: EFFI) (“Efftec” or the “Company”) is pleased to announce the acquisition of Teligent Care, Inc. (“Teligent”). Teligent has been fully acquired by Efftec, with Efftec remaining as the surviving entity.  Pursuant to the terms of this transaction, shareholders of Teligent have been issued seven million restricted shares of Efftec. 

The Company intends to change its name to “Teligent Care, Inc.” as well as seek a new ticker symbol to better reflect its new business model and enterprise.  In accordance with the terms of the acquisition agreement, Teligent’s CEO, Mr. Paul Cristiano, has joined Efftec as a member of its Board of Directors alongside Efftec’s current CEO, Bruce Collett.

Shareholders and interested parties are invited to visit https://www.teligentcare.com for information on the Company and its subsidiaries.  The website will be updated regularly to inform our shareholders of all business developments, including acquisitions, mergers and partnerships.

“After an exhaustive search of potential acquisitions, we are incredibly excited to have closed this transaction. We believe that the acquisition of Teligent will greatly enhance Efftec’s shareholder value.  Furthermore, the company has the potential to become a leading competitor in the field of specialized telemedicine.”  Bruce Collett, CEO of Efftec International, commented.  Bruce continued that “In the coming weeks, we will have a chance to more fully elaborate the details of Teligent’s management, business model, accomplishments thus far and plans for the future.”

Paul Cristiano responded: “We thank Efftec’s shareholders and its Board for their vote of confidence and for supporting our vision.  Our goal is to become the preeminent provider of specialized telemedicine services and advanced technologies in the healthcare field. As mentioned by Bruce, I look forward to the opportunity to more fully introduce ourselves and our company to the investing public.” 

About Teligent Care, Inc.

Teligent Care is a healthcare company designed to acquire and manage organizations and oversee strategic partners that work interdependently with its fully-owned subsidiary Telecare Partners Group (TPG).  TPG serves the skilled nursing facility sector with specialized and fully-customized telemedicine programs that contain costs, improve productivity, and enhance the quality of medical encounters.  Companies under the Teligent Care brand apply advanced telemedicine technology to deliver on-demand remote medical diagnosis to patients when an on-site doctor is not readily available and critical care is needed.  The company is based in Avon, Connecticut where it serves clients on a national basis.  

About Efftec International

Efftec International, Inc (EFFI: OTC) is a diversified holding company whose strategic plan is to acquire interests in young businesses, and provide financing, advice and guidance to assist them in realizing their potential.  It continues to identify and evaluate potential acquisitions that its management believes will create shareholder value and a return on investment. Additional information is available in its filings on otcmarkets.com.  For additional information please email investor@teligentcare.com.

Press Releases may include forward-looking statements. In particular, the words “believe,” “may,” “could,” “should,” “expect,” “anticipate,” “estimate,” “project," "propose," "plan," "intend," and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company.

Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Efftec International, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Efftec International, Inc. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company’s ability identify a suitable business model for the corporation.

Contact for information about the company,

Bruce Collett, CEO Efftec International, Inc.

investor@teligentcare.com, or 959-456-0300.

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
17 Feb
VWS
  Jeg har nu haft lidt tid til at læse det seneste årsregnskab fra Vestas. Jeg har forsøgt at opsumm..
62
21 Feb
VELO
Især 2 ting har fanget min opmærksomhed i de seneste døgn. 1) Astellas er udtrådt af AST )American S..
22
15 Feb
VELO
Jeg kan se på FB-gruppen at er der en diskussion omkring præparatet fra Hansa Medical det evt. ramme..
19
19 Feb
FING-B
Så lukkede FPC over den gamle modstand i dag i 19,55 modstanden var 19,47 og næste stop er nu 21,786..
18
15 Feb
VELO
Jeg har solgt mine Veloxis-aktier, for der er nogle mekanismer i stigningerne i både Chemometec og i..
18
21 Feb
CHEMM
Vi sidder her under træet og bliver helt skizofrene. Hvad skete der lige her. Tælleren tog et hop op..
17
18 Feb
VWS
VESTAS LEADS BREAK-AWAY GROUP OF ONSHORE TURBINE MAKERS (fra 16% til 22% af det totale marked for la..
17
18 Feb
PNDORA
Det er netop kommet frem, at tyske BAFIN, svarende til Finanstilsynet i Dk., har forbudt short posit..
17
19 Feb
VELO
Til dem af jer der ikke er med i FB gruppen: Canada havde, sammen med US, lukket i går. Teorien er, ..
16
18 Feb
CHEMM
Puha, ja hvad venter vi nu på,…… vi trofaste og frelste Chemo aktionærer, Noten, den romantiske og ..
15

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen
2
Bragar Eagel & Squire, P.C. is Investigating Domino’s Pizza, Inc. (DPZ) on Behalf of Stockholders and Encourages DPZ Investors to Contact the Firm
3
Melinta Therapeutics Announces One-for-Five Reverse Stock Split
4
Odyssey Moon Extends Its Heartfelt Congratulations to SpaceIL for the Successful Launch of the First Non-Governmental Spacecraft to the Moon
5
Bragar Eagel & Squire, P.C. is Investigating Vanda Pharmaceuticals Inc. (VNDA) on Behalf of Stockholders and Encourages VNDA Investors to Contact the Firm

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 February 2019 09:08:48
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB3 - 2019-02-22 10:08:48 - 2019-02-22 09:08:48 - 1000 - Website: OKAY